

Increasing Multidrug Resistance in *Helicobacter pylori* Strains Isolated from Children and Adults in Mexico

JAVIER TORRES,^{1*} MARGARITA CAMORLINGA-PONCE,¹ GUILLERMO PÉREZ-PÉREZ,²
ARMANDO MADRAZO-DE LA GARZA,³ MARGARITA DEHESA,⁴
GERARDO GONZÁLEZ-VALENCIA,¹ AND ONOFRE MUÑOZ¹

Unidad de Investigación Médica en Enfermedades Infecciosas,¹ Departamento de Gastroenterología, Hospital de Pediatría,³ and Departamento de Gastroenterología, Hospital de Especialidades,⁴ Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Mexico City, Mexico, and Division of Infectious Diseases, New York University, New York, New York²

Received 22 December 2000/Returned for modification 14 March 2001/Accepted 30 April 2001

The susceptibilities to three antimicrobials of 195 *Helicobacter pylori* strains isolated from Mexican patients is reported; 80% of the strains were resistant to metronidazole, 24% were resistant to clarithromycin, and 18% presented a transient resistance to amoxicillin. Resistance to two or more antimicrobials increased significantly from 1995 to 1997.

Eradication of *Helicobacter pylori* infection is the most effective means to cure peptic ulcer diseases and prevent possible recurrent episodes. The most common treatment regimens include a proton pump inhibitor plus two of the following antimicrobial agents: amoxicillin; clarithromycin; or metronidazole or tetracycline. *H. pylori* resistance to metronidazole and clarithromycin has increased worldwide (5, 15). Resistance to amoxicillin has been reported (10); however, this phenomenon is rare and unstable (2).

Indications for treatment have been extended (3), and with a more extended use of antibiotics, the probability of selection of resistant strains increases.

We report here our findings on antimicrobial susceptibility patterns among *H. pylori* strains isolated from children and adults during a 3-year period in Mexico.

Strains. One hundred ninety-five *H. pylori* strains isolated during the period from 1995 to 1997 were studied: 51 strains were isolated from children (mean age, 11 ± 4 years) with nonulcer dyspepsia (23 males and 28 females), whereas 144 strains were isolated from adults (mean age, 52 ± 17 years), 48 with nonulcer dyspepsia and 96 with peptic ulcers (93 males and 51 females). All patients were seen at the Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, in Mexico City, Mexico, and had no history of eradication treatment. Organisms were recovered from antrum and corpus gastric biopsies and identified by morphology and biochemical tests. Organisms were stored at -70°C in 20% glycerol-brain heart infusion broth until tested.

Antimicrobial susceptibility assay. Susceptibility to amoxicillin, clarithromycin, and metronidazole was determined by the Epsilometer test (E test; AB Biodisk, Solna, Sweden) (4).

H. pylori isolates were grown for 2 days on Columbia blood agar plates; growth was suspended in Columbia broth to achieve a McFarland opacity of 3 and spread on blood agar plates. The antimicrobial drug strip was placed on the plate and incubated at 37°C for 72 h in an incubator with a 9% CO₂ atmosphere (Nuare, Plymouth, Minn.). The MIC was defined by the point of intersection of the inhibitory zone with the strip (4). To confirm results, each strain was tested at least twice. The cutoff values for susceptibility were 8 µg/ml for metronidazole, 4 µg/ml for amoxicillin, and 2 µg/ml for clarithromycin (1, 10).

The susceptibility pattern obtained for the *H. pylori* isolates is described in Table 1. The rate of resistance to metronidazole was high (76.9%); resistance to clarithromycin was moderate (24%). Resistance to amoxicillin was observed in 18.5% of the isolates; however, resistance disappeared after a single passage or after freezing the strains. In contrast, resistance to clarithromycin and metronidazole remained unchanged after passage or freezing. Of interest, 30.7% of isolates were multidrug resistant, 17.9% to metronidazole and clarithromycin and 12.8% to metronidazole and amoxicillin; 8.7% were resistant to all three antibiotics tested. The distribution of MICs of the three antibiotics for the 110 *H. pylori* strains isolated during 1997 is presented in Fig. 1.

The yearly rate of resistance during the period from 1995 to 1997 was studied (Fig. 2). Resistance to metronidazole was similar throughout the 3 years; in contrast, resistance to amoxicillin and clarithromycin increased significantly during the period of study (Fig. 2a). Resistance to clarithromycin increased from 10% in 1995 to 27% in 1997, whereas resistance to amoxicillin increased from 13% in 1995 to 26% in 1997. Multidrug resistance also increased during this period (Fig. 2b); the rising trend was significant for resistance to metronidazole and clarithromycin (χ^2 for linear trend = 8.073; $P = 0.004$) as well as for resistance to all three antibiotics tested ($\chi^2 = 5.94$; $P =$

* Corresponding author. Mailing address: Prol. Av. Centenario 1707-39, Bosques de Tarango, México, D.F., CP 01580, México. Phone: 52 5 627-6940. Fax: 52 5 627-6949. E-mail: jtorresl@axtel.net.

TABLE 1. Susceptibility patterns of *H. pylori* strains isolated from Mexican children and adults

Antibiotic(s)	No. (%) of resistant isolates		
	Children (n = 51)	Adults (n = 144)	Total ^a (n = 195)
Metronidazole	40 (78.4)	110 (76.3)	150 (76.9)
Clarithromycin	11 (21.6)	36 (25)	47 (24)
Amoxicillin ^b	8 (15.7)	28 (19.4)	36 (18.5)
Metronidazole + clarithromycin	9 (17.6)	26 (18)	35 (17.9)
Metronidazole + amoxicillin	6 (11.8)	19 (13.2)	25 (12.8)
Metronidazole + clarithromycin + amoxicillin	2 (4)	15 (10.4)	17 (8.7)

^a Differences were not significant for any comparison between children and adults.

^b Resistance to amoxicillin was transient in all cases; it was lost after passage or freezing.

0.01). There was no difference in the rate of resistance to any of the three antibiotics tested when we compared children versus adults, men versus women, or ulcer disease isolates versus nonulcer dyspepsia isolates.

In this study we report the susceptibility of *H. pylori* strains from Mexico, a country with a high prevalence of infection (13), to the most commonly used antibiotics. A high rate of resistance to metronidazole was found consistently throughout the 3 years of the study; these results are similar to frequencies reported for other developing countries (9). In Mexico, metronidazole has commonly been used to treat diarrheal diseases for many years (12); this is probably the cause of the high rate of resistance to this antibiotic. We could not demonstrate higher metronidazole resistance in females, despite the fact that gender has been suggested to be a risk factor for resistance to metronidazole, probably because of its use in the treatment of gynecologic infections (14). The value of the E test for testing susceptibility to metronidazole has been questioned recently (11); however, when assay conditions are carefully controlled, results are comparable to those of agar dilution and disk diffusion (8, 14). We found moderate resistance to clarithromycin that increased yearly. Previous reports have suggested that the rate of resistance to clarithromycin is

higher in strains isolated from children than in strains from adults (7); however, we found no difference between the two groups.

Recent reports have documented the existence of strains with resistance to amoxicillin, although in most cases this resistance was demonstrated to be transitory (2). In isolates from our community, a moderate prevalence of amoxicillin resistance was observed; nevertheless, this was unstable in all cases.

Few studies have reported the rate of multidrug resistance in *H. pylori* isolates. In this study, we document resistance to at least two antimicrobial agents in 30% of the isolates. A high rate of resistance to both metronidazole and clarithromycin (18%) was found; resistance to either of these two antimicrobials is a risk factor for treatment failure (5). We are concerned that resistance to both clarithromycin and amoxicillin is continuously increasing in our community; in 1997 the rate of resistance to either drug was over 25%, suggesting that eventually these antimicrobials will lose their efficacy against *H. pylori* infections. Resistance to all three antimicrobial drugs tested rose from 4% in 1995 to 12% in 1997. These results stress the need for alternative therapies. Clinicians in our community at present are recommending the use of furazolidone and tetracycline as alternatives; the use of these antibiotics in





FIG. 1. Distribution of metronidazole, clarithromycin, and amoxicillin MICs for 110 *H. pylori* strains isolated during 1997.

a



b




FIG. 2. Prevalence of *H. pylori* strains resistant to amoxicillin, clarithromycin, and metronidazole isolated in Mexico City during the period from 1995 to 1997. The numbers of strains studied were 30 in 1995, 43 in 1996, and 110 in 1997. (a) Resistance to amoxicillin or to clarithromycin; (b) resistance to two or three of the antibiotics tested. The trend was significant for metronidazole and clarithromycin ($P = 0.004$) and for the three antibiotics ($P = 0.01$).

combination with ranitidine bismuth citrate has been shown to be effective and inexpensive in other communities (6).

In conclusion, we documented a high rate of resistance to metronidazole and a rising resistance to both clarithromycin and amoxicillin in our community. It is of concern to us that multidrug resistance to these antimicrobial agents is also rising significantly.

This project was supported by CONACYT (grant 28040 M), BykGulden-México, and the Coordinación de Investigación, Instituto Mexicano del Seguro Social, México.

REFERENCES

- DeLoney, C. R., and N. L. Schiller. 2000. Characterization of an in vitro-selected amoxicillin-resistant strain of *Helicobacter pylori*. *Antimicrob. Agents Chemother.* 44:3368-3373.
- Dore, M. P., G. Realdi, I. Mura, M. S. Ostato, D. Y. Graham, and A. R.

- Sepulveda. 1997. Amoxicillin-resistant strains of *H. pylori* undergo reversible loss of resistance after storage. *Gut* **41**(Suppl. 1):A8.
3. **The European Helicobacter pylori Study Group.** 1997. Current European concepts in the management of *Helicobacter pylori* infection. The Maastricht Consensus Report. *Gut* **41**:8–13.
 4. **Glupczynski, Y., M. Labbe, H. Willy, and E. C. Yourassowsky.** 1991. Evaluation of the E test for quantitative antimicrobial susceptibility testing of *Helicobacter pylori*. *J. Clin. Microbiol.* **29**:2072–2075.
 5. **Graham, D. Y.** 1998. Antibiotic resistance in *Helicobacter pylori*: implications for therapy. *Gastroenterology* **115**:1272–1277.
 6. **Graham, D. Y., M. S. Osato, J. Hoffman, A. R. Opekun, S. Y. Anderson, and H. M. T. El-Zimaity.** 2000. Furazolidone combination therapies for *Helicobacter pylori* infection in the United States. *Aliment. Pharmacol. Ther.* **14**: 211–215.
 7. **Jesch, I., A. Kindermann, S. Krauss-Etschmann, I. Autenrieth, N. Lehn, and S. Koletzko.** 1999. Prevalence of clarithromycin-resistant *H. pylori*-strains in children: effect of therapy. *Gut* **45**(Suppl. III):A93.
 8. **Kalach, N., M. Bergeret, P. H. Benhamou, C. Dupont, and J. Raymond.** 2001. High levels of resistance to metronidazole and clarithromycin in *Helicobacter pylori* strains in children. *J. Clin. Microbiol.* **39**:394–397.
 9. **Mégraud, F.** 1998. Epidemiology and mechanism of antibiotic resistance in *Helicobacter pylori*. *Gastroenterology* **115**:1278–1282.
 10. **Mendonca, S., C. Ecclissato, M. S. Sartori, A. P. Ortiz, R. Aparecida, and M. D. Pedrazzoli.** 2000. Prevalence of *Helicobacter pylori* resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. *Helicobacter* **5**:79–83.
 11. **Piccolomini, R., G. D. Bonaventura, G. Catamo, F. Carbone, and M. Neri.** 1997. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of *Helicobacter pylori* strains to 20 antimicrobial agents. *Ann. Intern. Med.* **109**:11–17.
 12. **Torres, J., S. Gonzalez-Arroyo, R. Pérez, and O. Muñoz.** 1995. Inappropriate treatment in children with bloody diarrhea: clinical and microbiological studies. *Arch. Med. Res.* **26**:23–29.
 13. **Torres, J., Y. Leal-Herrera, G. I. Pérez-Pérez, A. Gómez, M. Camorlinga-Ponce, R. Cedillo-Ribera, R. Tapia-Conyer, and O. Muñoz.** 1998. A community-based seroepidemiological study of *Helicobacter pylori* infection in Mexico. *J. Infect. Dis.* **178**:1089–1094.
 14. **van der Wouden, E. J., J. C. Thijs, A. A. van Zwet, and J. H. Kleibeuker.** 2000. Nitroimidazole resistance in *Helicobacter pylori*. *Aliment. Pharmacol. Ther.* **14**:7–14.
 15. **van der Wouden, E. J., A. A. van Zwet, J. C. Thijs, G. D. C. Vosmaer, and J. H. Kleibeuker.** 1997. Rapid increase in the prevalence of metronidazole-resistant *Helicobacter pylori* in The Netherlands. *Emerg. Infect. Dis.* **3**:385–389.